Surgical Science Sweden AB (publ) (SUS) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi, everyone, and welcome to this earnings call for Certical Science for the first quarter of 2026. My name is Tom Englund. I'm the CEO. And with me today, I have Anna Ahlberg, our CFO. So we'll start with a walkthrough of quarter one and the numbers, and then we'll open up for questions. So quarter one is a quarter with two stories running in parallel. On the surface, reported sales are down 6% to 236 million SEC. But once you strip out the currency headwind that we had and the dollar moved significantly against us, the underlying business grew by 4%. And if you look at cash flow, we generated 65 million sec from operations, which is a very strong number and significantly better than the same quarter last year. So the business itself is in good shape. Adjusted EBIT came in at 28 million SEC or 12%. That's in line with last year. And when you adjust for currencies, it's actually around 16% right at our target level. So the headwind here is, as with the revenue, almost entirely a currency story and not an operational one. Throughout the quarter, we're executing on the strategy we laid out at the Capital Markets Day in December. And I feel good about where we're headed. So now I want to take you through the different parts of the business. Educational products grew by 6% or 14% growth in local currencies. And there are some exciting things happening here that I want to highlight. EMEA had an exceptional quarter. Revenue was up 80% or over 80%, driven by a number of strong deals across Eastern Europe. And the UK, which, as you know, is where our Certical Science UK team operates, posted one of its best quarters ever. Sales in pound sterling for the quarter actually exceeded the total for all of 2025, which is a big statement. And it also tells me that the investment tha...